top of page
News, Events and Updates
Search
Anavex Life Sciences to Present at Noble Capital Markets' Thirteenth Annual Investor Conference
Jan 23, 2017
Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017
Jan 19, 2017
Anavex Life Sciences Obtains Permanent Dismissal of All Claims in Securities Lawsuit
Jan 3, 2017
Aanvex Life Sciences Reports Fiscal 2016 Financial Results
Dec 12, 2016
9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study
Dec 10, 2016
Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Alzheimer's Patients Study
Dec 8, 2016
Anavex Life Sciences to Present at Annual Mental Health Parity Addiction Equity Act Roundtable
Dec 1, 2016
Anavex Life Sciences Appoints Three Distinguished Researchers to Scientific Advisory Board
Nov 28, 2016
CTAD 2016 — Clinical Trials on Alzheimer's Disease
Nov 22, 2016
Anavex Life Sciences Announces Data on 41Week Treatment of ANAVEX 2-73 for Patients with Alzheimer's
Nov 22, 2016
Maxim Group LLC — Central Nervous System Disease Conference
Nov 14, 2016
26
27
28
29
30
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
